|1.||Oleykowski, Catherine A: 2 articles (01/2011 - 07/2009)|
|2.||Hardwicke, Mary Ann: 2 articles (01/2011 - 07/2009)|
|3.||Plant, Ramona: 2 articles (01/2011 - 07/2009)|
|4.||Locatelli, Franco: 1 article (01/2014)|
|5.||Bressanin, Daniela: 1 article (01/2014)|
|6.||Evangelisti, Cecilia: 1 article (01/2014)|
|7.||Pession, Andrea: 1 article (01/2014)|
|8.||Cappellini, Alessandra: 1 article (01/2014)|
|9.||Lonetti, Annalisa: 1 article (01/2014)|
|10.||Spartà, Antonino Maria: 1 article (01/2014)|
01/01/2011 - "59 Hematological cancer-derived cell lines were used as models for response where in vitro sensitivity to GSK1070916 was based on both time and degree of cell death. "
01/01/2011 - "High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916."
07/01/2009 - "Moreover, GSK1070916 inhibits the proliferation of tumor cells with EC(50) values of <10 nmol/L in over 100 cell lines spanning a broad range of tumor types. "
01/01/2011 - "Translation of predictive biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies, especially novel inhibitors such as GSK1070916. "
07/01/2009 - "These results show that GSK1070916 is a potent Aurora B/C kinase inhibitor that has the potential for antitumor activity in a wide range of human cancers."
|2.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
|1.||Biological Markers (Surrogate Marker)
|5.||4- (3- chloro- 2- fluorophenoxy)- 1- ((6- (1,3- thiazol- 2- ylamino)pyridin to 2-yl)methyl) cyclohexanecarboxylic acid
|6.||aurora kinase (aurora A kinase)
|1.||Heterologous Transplantation (Xenotransplantation)